As described above, telomerase is involved in resistance to the specific RTK FLT3 inhibitor [29], and there thus exists the possibility that DKC1, as a telomerase factor, may play a part in ccRCC patient response to Sunitinib. The gene discussed is FLT3; the disease is nonpapillary renal cell carcinoma.